Viatris Inc. (VTRS) Stock Analysis

Viatris reported 2025 total revenues of $14.30 billion across four segments — Developed Markets, Emerging Markets, JANZ, and Greater China — serving patients in more than 165 countries through retail and pharmacy establishments, wholesalers, governments, and institutions. The company employs more than 30,000 people and operates 27 manufacturing, packaging, and distribution sites globally, with centers in Pittsburgh, Pennsylvania; Shanghai, China; and Hyderabad, India. In February 2026, the company announced restructuring activities from its enterprise-wide strategic review targeting a global workforce reduction of up to 10% and $600-700 million in savings once fully implemented, with total pre-tax charges estimated at $700-850 million.

Viatris generates revenue from three portfolio pillars: generics (including Wixela Inhub, Breyna, and Venofer generics), established brands, and an expanding innovative pipeline. Products are distributed through retail and pharmacy channels, wholesalers, governments, institutions, and physicians. API manufacturing for certain products depends on a limited number of third-party suppliers, including through a manufacturing and supply agreement with the buyer of the divested India API business. Key pipeline assets in Phase 3 include selatogrel (cardiovascular), cenerimod (autoimmune), fast-absorbing meloxicam for acute pain, and phentolamine ophthalmic for presbyopia — the supplemental NDA for the latter was accepted by the FDA in February 2026 with action anticipated in the second half of 2026. The company faces persistent pricing pressure from China's centralized Volume-Based Procurement policy, where some molecules have seen price reductions as high as 96%, and from U.S. Most Favored Nation drug pricing programs whose scope may expand.